FDA OKs Merck clot drug

Share this article:

The FDA green-lighted Merck's anti-blood-clot drug vorapaxar, which will go by the brand name Zontivity.

Friday's approval is for reducing the risk of heart attack, stroke and cardiovascular death among patients who have already had a heart attack or have blocked arteries of the leg.

Reuters notes that approval was slow-going because of concerns about bleeding among clinical trial patients.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.